Pharma “leading the pack” despite shipping law issues

By Nick Taylor

- Last updated on GMT

Related tags: Pharma, Law

The shipping requirements of drugs means the TSA’s new law poses unique problems to the pharma industry, according to DHL, but experience of tight regulations should help companies achieve compliance.

Pharma shipments may be temperature controlled, use different pallet configurations, have boxes that cannot be opened and products that cannot be x-rayed, all of which create unique problems for companies trying to comply with the new law.

The US Transportation Security Administration (TSA) has created the law to address concerns about aircraft security. When the law comes into force on August 1 each individual unit in a pallet or shipment taking off in the US must be screened.

Enforcing this at airports would be too much for TSA resources, Lonnie Rockford, senior project manager for performance management at DHL, told in-PharmaTechnologist. Consequently, the TSA is granting facilities the right to screen before transport to airports.

Pharma companies operating shipping facilities which are incompliant with the law on August 1 will have to use airport screening. Rockford believes this would lead to service delays and possibly be detrimental to the stability of temperature controlled products.

Fortunately, pharma, having initially adopting “a wait and see attitude​”, has worked hard to gain TSA accreditation, according to Rockford. These efforts have been helped by the infrastructure already in place at pharma facilities and the experience of working to tight regulations.

For example, pharma operates very secure facilities, Rockford explained. Consequently some of the measures required by the TSA are already in place at pharma facilities.

Pharma is leading the pack in certification​”, said Rockford, adding that several have already been accredited by the TSA. Furthermore, DHL has been collaborating with companies, running a workshop in partnership with American Airlines Cargo to help explain the whole process.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more